Jufang Shi1, Guoxiang Liu2, Hong Wang1, Ayan Mao3, Chengcheng Liu1, Lanwei Guo4,1, Huiyao Huang1, Jiansong Ren1, Xianzhen Liao5, Yana Bai6, Xiaojie Sun7, Xinyu Zhu1,6, Jialin Wang8, Bingbing Song9, Jinyi Zhou10, Lin Zhu11, Haike Lei12, Yuqin Liu13, Yunyong Liu14, Lingbin Du15, Yutong He16, Kai Zhang1, Ni Li1, Wanqing Chen1, Min Dai1, Jie He17. 1. Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. 2. Department of Health Economics, School of Health Management/Public Health, Harbin Medical University, Harbin 150081, China. 3. Office of Public Health Strategic Information, Institute of Medical Information, Chinese Academy of Medical Sciences, Beijing 100020, China. 4. Department of Cancer Epidemiology, Henan Office for Cancer Control and Research, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China. 5. Hunan Office for Cancer Control and Research, Hunan Provincial Cancer Hospital, Changsha 410006, China. 6. Institute of Epidemiology and Health Statistics, Lanzhou University, Lanzhou 730000, China. 7. Center for Health Management and Policy, Key Lab of Health Economics and Policy, Shandong University, Jinan 250012, China. 8. Department of Public Health, Shandong Cancer Hospital Affiliated to Shandong University, Jinan 250117, China. 9. Heilongjiang Office for Cancer Control and Research, Affiliated Cancer Hospital of Harbin Medical University, Harbin 150081, China. 10. Institute of Chronic Non-communicable Diseases Prevention and Control, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China. 11. Teaching and Research Department, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi 830011, China. 12. Department of Cancer Research and Control Office, Chongqing University Cancer Hospital, Chongqing 400030, China. 13. Cancer Epidemiology Research Center, Gansu Provincial Cancer Hospital, Lanzhou 730050, China. 14. Cancer Prevention and Control Office of Liaoning Province, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang 110042, China. 15. Department of Cancer Prevention, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou 310022, China. 16. Cancer Institute, The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang 050011, China. 17. Department of Thoracic Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Abstract
OBJECTIVE: Colorectal cancer (CRC) causes a substantial burden of disease in China and the evidence of economic burden triggered is fundamental for priority setting. The aim of this survey was to quantify medical expenditures and the time trends for CRC diagnosis and treatment in China. METHODS: From 2012 to 2014, a hospital-based multicenter retrospective survey was conducted in 13 provinces across China. For each eligible CRC patient diagnosed from 2002 to 2011, clinical information and expenditure data were extracted using a uniform questionnaire. All expenditure data were reported in Chinese Yuan (CNY) using 2011 values. RESULTS: Of the 14,536 CRC patients included, the average age at diagnosis was 58.2 years and 15.8% were stage-I cases. The average medical expenditure per patient was estimated at 37,902 CNY [95 % confidence interval (95% CI): 37,282-38,522], and the annual average increase rate was 9.2% from 2002 to 2011 (P for trend <0.001), with a cumulative increase of 2.4 times (from 23,275 CNY to 56,010 CNY). The expenditure per patient in stages I, II, III and IV were 31,698 CNY, 37,067 CNY, 38,918 CNY and 42,614 CNY, respectively (P<0.001). Expenditure significantly differed within various subgroups. Expenses for drugs contributed the largest proportion (52.6%). CONCLUSIONS: These conservative estimates illustrated that medical expenditures for CRC diagnosis and treatment in tertiary hospitals in China were substantial and increased rapidly over the 10 years, with drugs continually being the main expense by 2011. Relatively, medical expenditures are lower for CRC in the earlier stages. These findings will facilitate the economic evaluation of CRC prevention and control in China.
OBJECTIVE: Colorectal cancer (CRC) causes a substantial burden of disease in China and the evidence of economic burden triggered is fundamental for priority setting. The aim of this survey was to quantify medical expenditures and the time trends for CRC diagnosis and treatment in China. METHODS: From 2012 to 2014, a hospital-based multicenter retrospective survey was conducted in 13 provinces across China. For each eligible CRC patient diagnosed from 2002 to 2011, clinical information and expenditure data were extracted using a uniform questionnaire. All expenditure data were reported in Chinese Yuan (CNY) using 2011 values. RESULTS: Of the 14,536 CRC patients included, the average age at diagnosis was 58.2 years and 15.8% were stage-I cases. The average medical expenditure per patient was estimated at 37,902 CNY [95 % confidence interval (95% CI): 37,282-38,522], and the annual average increase rate was 9.2% from 2002 to 2011 (P for trend <0.001), with a cumulative increase of 2.4 times (from 23,275 CNY to 56,010 CNY). The expenditure per patient in stages I, II, III and IV were 31,698 CNY, 37,067 CNY, 38,918 CNY and 42,614 CNY, respectively (P<0.001). Expenditure significantly differed within various subgroups. Expenses for drugs contributed the largest proportion (52.6%). CONCLUSIONS: These conservative estimates illustrated that medical expenditures for CRC diagnosis and treatment in tertiary hospitals in China were substantial and increased rapidly over the 10 years, with drugs continually being the main expense by 2011. Relatively, medical expenditures are lower for CRC in the earlier stages. These findings will facilitate the economic evaluation of CRC prevention and control in China.
Authors: Gery P Guy; Donatus U Ekwueme; K Robin Yabroff; Emily C Dowling; Chunyu Li; Juan L Rodriguez; Janet S de Moor; Katherine S Virgo Journal: J Clin Oncol Date: 2013-09-16 Impact factor: 44.544
Authors: Carlos K H Wong; Cindy L K Lam; Jensen T C Poon; Sarah M McGhee; Wai-Lun Law; Dora L W Kwong; Janice Tsang; Pierre Chan Journal: J Eval Clin Pract Date: 2011-11-23 Impact factor: 2.431
Authors: Angela B Mariotto; K Robin Yabroff; Yongwu Shao; Eric J Feuer; Martin L Brown Journal: J Natl Cancer Inst Date: 2011-01-12 Impact factor: 13.506
Authors: L W Guo; C L Shi; H Y Huang; L Wang; X P Yue; S Z Liu; J Li; K Su; M Dai; X B Sun; J F Shi Journal: Zhonghua Liu Xing Bing Xue Za Zhi Date: 2017-01-10
Authors: Haike Lei; Lin Lei; Jufang Shi; Yongzhong Wu; Ling Liang; Huiyao Huang; Mei He; Fangzhou Bai; Maomao Cao; Hui Qiu; Yuting Wang; Chengcheng Liu; Jia Du; Hong Wang; Yan Zhang; Mengdi Cao; Ji Peng; Ni Li; Chunfeng Qu; Min Dai; Wanqing Chen; Jie He Journal: Chin J Cancer Res Date: 2020-08 Impact factor: 4.026
Authors: Ria Garg; Vicki Cheng; Ursula Ellis; Vanay Verma; Helen McTaggart-Cowan; Stuart Peacock; Jonathan M Loree; Mohsen Sadatsafavi; Mary A De Vera Journal: BMC Health Serv Res Date: 2022-08-30 Impact factor: 2.908